Value of Impedance Cardiography during 6‐Minute Walk Test in Pulmonary Hypertension

Methods that predict prognosis and response to therapy in pulmonary hypertension (PH) are lacking. We tested whether the noninvasive estimation of hemodynamic parameters during 6‐minute walk test (6MWT) in PH patients provides information that can improve the value of the test.

[1]  Horst Olschewski,et al.  Updated clinical classification of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.

[2]  R. Dweik,et al.  Heart rate recovery predicts clinical worsening in patients with pulmonary arterial hypertension. , 2012, American journal of respiratory and critical care medicine.

[3]  S. Rich,et al.  Noninvasive cardiac output measurements in patients with pulmonary hypertension , 2012, European Respiratory Journal.

[4]  P. Gargiulo,et al.  Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. , 2012, Journal of the American College of Cardiology.

[5]  S. Rich.  The 6-minute walk test as a primary endpoint in clinical trials for pulmonary hypertension. , 2012, Journal of the American College of Cardiology.

[6]  L. Nery,et al.  Signal‐morphology impedance cardiography during incremental cardiopulmonary exercise testing in pulmonary arterial hypertension , 2012, Clinical physiology and functional imaging.

[7]  I. Nasis,et al.  On- and off-exercise kinetics of cardiac output in response to cycling and walking in COPD patients with GOLD Stages I–IV , 2012, Respiratory Physiology & Neurobiology.

[8]  R. Dweik,et al.  Comparison of baseline predictors of prognosis in pulmonary arterial hypertension in patients surviving ≤2 years and those surviving ≥5 years after baseline right-sided cardiac catheterization. , 2012, The American journal of cardiology.

[9]  R. Dweik,et al.  Determination Of Hemodynamic Parameters During 6-Minute Walk Test In Pulmonary Hypertension , 2012, ATS 2012.

[10]  H. Palevsky,et al.  Validation of 6-Minute Walk Distance as a Surrogate End Point in Pulmonary Arterial Hypertension Trials , 2012, Circulation.

[11]  J. Neder,et al.  Heart rate recovery in pulmonary arterial hypertension: relationship with exercise capacity and prognosis. , 2012, American heart journal.

[12]  R. Tuder,et al.  Targeting energetic metabolism: a new frontier in the pathogenesis and treatment of pulmonary hypertension. , 2012, American journal of respiratory and critical care medicine.

[13]  A. Tonelli,et al.  Value of Impedance Cardiography in Patients Studied for Pulmonary Hypertension , 2011, Lung.

[14]  R. Dweik,et al.  Strengths and limitations of the six-minute-walk test: a model biomarker study in idiopathic pulmonary fibrosis. , 2011, American journal of respiratory and critical care medicine.

[15]  N. Westerhof,et al.  Exercise stroke volume and heart rate response differ in right and left heart failure , 2010, European journal of heart failure.

[16]  R. Naeije,et al.  Prognostic significance of sympathetic nervous system activation in pulmonary arterial hypertension. , 2010, American journal of respiratory and critical care medicine.

[17]  Horst Olschewski,et al.  Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. , 2010, Journal of the American College of Cardiology.

[18]  R. Arena,et al.  Cardiopulmonary exercise testing in patients with pulmonary arterial hypertension: an evidence-based review. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[19]  P. Argiento,et al.  Exercise stress echocardiography for the study of the pulmonary circulation , 2009, European Respiratory Journal.

[20]  B. Brundage,et al.  Tadalafil Therapy for Pulmonary Arterial Hypertension , 2009, Circulation.

[21]  M. Dörr,et al.  Impaired cardiac autonomic control relates to disease severity in pulmonary hypertension , 2009, European Respiratory Journal.

[22]  T. Fleming,et al.  Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. , 2008, Annals of internal medicine.

[23]  M. Humbert,et al.  Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension , 2008, European Respiratory Journal.

[24]  B. Wiens,et al.  Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2 , 2008, Circulation.

[25]  A. Borghi-Silva,et al.  Kinetics of muscle deoxygenation are accelerated at the onset of heavy-intensity exercise in patients with COPD: relationship to central cardiovascular dynamics. , 2008, Journal of applied physiology.

[26]  L. Tavazzi,et al.  A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. , 2007, American heart journal.

[27]  Andrzej Kutarski,et al.  Impedance cardiography: A valuable method of evaluating haemodynamic parameters. , 2007, Cardiology journal.

[28]  Andrew R. Hsu,et al.  Sildenafil improves cardiac output and exercise performance during acute hypoxia, but not normoxia. , 2006, Journal of applied physiology.

[29]  J. Marcus,et al.  Impaired stroke volume response to exercise in pulmonary arterial hypertension. , 2006, Journal of the American College of Cardiology.

[30]  M. Humbert,et al.  Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension , 2006, European Respiratory Journal.

[31]  T. Fleming,et al.  Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.

[32]  A. Charloux,et al.  Does thoracic bioimpedance accurately determine cardiac output in COPD patients during maximal or intermittent exercise? , 2005, Chest.

[33]  R. Naeije,et al.  Exercise testing in pulmonary arterial hypertension and in chronic heart failure , 2004, European Respiratory Journal.

[34]  W. Seeger,et al.  Inhaled iloprost for severe pulmonary hypertension. , 2002, The New England journal of medicine.

[35]  S. Rich,et al.  Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.

[36]  Avid,et al.  BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION , 2002 .

[37]  ATS statement: guidelines for the six-minute walk test. , 2002, American journal of respiratory and critical care medicine.

[38]  Martin Buchheit,et al.  Non-invasive cardiac output evaluation during a maximal progressive exercise test, using a new impedance cardiograph device , 2001, European Journal of Applied Physiology.

[39]  B. Brundage,et al.  Responses to constant work rate bicycle ergometry exercise in primary pulmonary hypertension: the effect of inhaled nitric oxide. , 2000, Journal of the American College of Cardiology.

[40]  Jean Lonsdorfer,et al.  A new impedance cardiograph device for the non-invasive evaluation of cardiac output at rest and during exercise: comparison with the “direct” Fick method , 2000, European Journal of Applied Physiology.

[41]  S J Jay,et al.  Reference equations for the six-minute walk in healthy adults. , 2000 .

[42]  Stuart Rich,et al.  Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.

[43]  M. Fujita,et al.  Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. , 2000, American journal of respiratory and critical care medicine.

[44]  C. Tei,et al.  Diastolic Bulging of the Interventricular Septum Toward the Left Ventricle: An Echocardiographic Manifestation of Negative Interventricular Pressure Gradient Between Left and Right Ventricles During Diastole , 1980, Circulation.